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Ovarian cancer is the sixth most common cancer among women
worldwide, and the leading cause of death from gynaecological
neoplasias (Parkin et al, 1999). The lack of symptoms during the
early stages of the disease results in the majority of women
presenting with advanced tumours that do not respond well to
treatment. Tumorigenesis is widely accepted as a multi-step
process driven by the accumulation of molecular changes leading
to alterations in the expression or function of numerous genes
which may be classified as either oncogenes or tumour suppressor
genes. Tumour suppressor genes have been further divided into
Type I, which are usually inactivated by mutation, and Type II,
which are usually inactivated by loss of expression but are not
commonly mutated (Sager, 1997). The identification and charac-
terization of these changes will lead to an improved understanding
of the molecular basis of this disease and may provide opportun-
ities for early disease detection and novel therapeutic approaches
that are urgently required. 
Some progress has been made in identifying genes with muta-
tions or altered expression patterns in ovarian adenocarcinomas.
For example, p53 mutations have been found in 37% of stage I and
II tumours and 58% of stage III and IV tumours (Shelling et al,
1995) and the K-ras oncogene is activated in a proportion of these
tumours, particularly those of mucinous histology (Mandai et al,
1998). There are also a number of tumour suppressor genes (e.g.
PTEN, CDKN2A, BRCA1 and BRCA2) in which mutations have
been reported in ovarian tumours at a low frequency (Merajver
et al, 1995; Foster et al, 1996; Shih et al, 1997; Obata et al, 1998).
It has recently been demonstrated that the expression of several
putative tumour suppressor genes such as OVCA1, Disabled-2,
GPC3,  NOEY2 and  SPARC is lost in a proportion of ovarian
adenocarcinomas (Mok et al, 1996, 1998; Bruening et al, 1999;
Lin et al, 1999; Yu et al, 1999). In addition, the c-erbB-2, c-fms,
and c-myc, oncogenes are commonly overexpressed in ovarian
cancers (Yasue et al, 1987; Zhou et al, 1988; Kohler et al, 1989;
Slamon et al, 1989). Despite this progress, the molecular changes
associated with the development and progression of this disease
remain unclear. There is increasing evidence for heterogeneity in
the pathway to malignancy with respect to histologic sub-types
(Mandai et al, 1998; Obata et al, 1998; Wright et al, 1999) but
there is no established model for ovarian tumorigenesis. 
There are a number of different methods for the comparison of
global gene expression patterns between two or more tissue
sources. These include differential display (Liang and Pardee,
1992), subtractive hybridization (Lee et al, 1991), serial analysis
of gene expression (SAGE) (Velculescu et al, 1995), EST database
comparisons (Vasmatzis et al, 1998), high-density cDNA microar-
rays (Schena et al, 1995), and commercially available cDNA
arrays that consist of hundreds of cDNAs immobilized to nylon
membranes (Peitu et al, 1996). We have investigated changes in
gene expression patterns in ovarian adenocarcinoma by examining
differences between an immortalized human ovarian surface
epithelial cell line (HOSE) and 3 ovarian cancer cell lines using
the cDNA Atlas Array available from Clontech, Inc. This method
allows the rapid and simultaneous comparison of the expression of
hundreds of genes in multiple cell lines. The reduced levels of
expression of one gene, Id3, in the ovarian cancer cell lines,
combined with its chromosomal localization at 1p36 (which we
have shown is a common region of LOH in ovarian cancer
(Imyanitov et al, 1999)), suggested that it may be important in
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ovarian tumorigenesis. This report presents the results of the
analysis of Id3 expression in HOSE and ovarian cancer cell lines
as well as further characterization of Id3 in primary ovarian
tumours by expression and mutation analysis. 
MATERIALS AND METHODS 
Cell lines, ovarian surface epithelium cultures and
primary tumours 
Human ovarian surface epithelial cell lines (HOSE) 17.1 and 1.1,
immortalized with a retroviral vector expressing human papillo-
mavirus oncogenes (Tsao et al, 1995), were maintained in a
medium composed of 1:1 M199:MCDB105 with 10% FCS. The
HEY ovarian cancer cell line was maintained in MEMa medium
with 10% FCS (Buick et al, 1985). The remainder of the ovarian
cancer cell lines – OAW 42 (Wilson, 1984), OAW 28+53 (Wilson
et al, 1987), PEO1 and PEO4 (Wolf et al, 1987), PEO14 (Langdon
et al, 1988), JAM (Ward et al, 1987), SKOV3 (Fogh and Trempe,
1975), COLO316 (Woods et al, 1979), CAOV3 (Wong et al,
1999), OVCAR-3 (Hamilton et al, 1983), and 27/87 (derived by T
Hurst) – were all maintained in RPMI 1640 with 10% FCS. Cells
were harvested for RNA and protein isolation at about 80%
confluence. The cell lines OAW 42, PEO1, PEO4, PEO14, JAM,
SKOV3 and COLO316 were derived from serous tumours, and
27/87 from an endometrioid tumour. 
Primary cultures of human ovarian surface epithelial cells were
prepared according to the method of Kruk et al (1990). Epithelial
cells were obtained by scraping contaminating stromal cells away
from proliferating epithelial sheets and cultured in 1:1 MCDB105:
Medium 199 with Earles’ salts, supplemented with 20 ng ml–1
epidermal growth factor, 400 ng ml–1 hydrocortisone and 15% fetal
calf serum. The distinctive cellular morphology was used to certify
that the cultures were epithelial cells. In one case, RNA was
extracted directly from the peeled epithelial cells without
culturing.
DNA was obtained from 95 patients with ovarian neoplasms
undergoing surgery. There were 67 serous tumours, 12
endometrioid tumours, 9 mucinous tumours, 5 clear-cell tumours,
and 2 tumours of mixed histology. The series included 1 benign
and 10 low-malignant potential (LMP) tumours as well as 84
malignant tumours. All patients were staged at laparotomy, in
accordance with the recommendations of the International
Federation of Gynaecology and Obstetrics (FIGO). Of the LMP
tumours, 5 were FIGO stage 1 and 4 were stage 3 (one was of
unknown stage) and of the malignant tumours, 7 were stage 1, 4
stage 2, 65 stage 3 and 8 stage 4. Constitutional DNA from peri-
pheral blood was available for all cases. RNA was available from
a subset of 38 tumours. 
Isolation of DNA and RNA 
Tumour tissue was dissected free from necrotic and connective
tissue, and mechanically dispersed prior to collagenase treatment
(0.1 mg ml–1 in Hanks balanced salt solution). Dead and red cells
were then removed by ficoll-paque, and genomic DNA was
extracted by the salting-out method as described elsewhere
(Chenevix-Trench et al, 1992). The purity of the resulting DNA is
supported by the high frequency of LOH on chromosome 17
detected in ovarian tumour DNA prepared by this method (Leary
et al, 1995). Total RNA was extracted from primary tumours or
sub-confluent cultured cell lines using the Tri-reagent (Sigma),
following the manufacturers’ instructions. PolyA+ RNA was
prepared from this total RNA using Dynabeads (Dynal) according
to the recommended protocol. 
Hybridization to array membrane 
Hybridizations to the Atlas Array (Clontech, Inc.) were performed
strictly as recommended by the manufacturer. Probes were
prepared by reverse transcription from 1 mg of polyA+ RNA and
hybridized to the membrane overnight in ExpressHyb (Clontech,
Inc.) solution at 68˚C, followed by stringent washing and autoradio-
graphy. The names of all genes and controls on the array, and their
accession numbers, can be obtained from http://www.clontech.
com/clontech/APR97UPD/Atlaslist.html. 
Semi-quantitative RT-PCR 
RT-PCR was performed on 1 mg of total RNA in a total volume of
20 ml incorporating 33P-dATP using standard PCR cycling condi-
tions. Primer pairs were designed to amplify 300–500 bp cDNA
fragments and spanned at least 1 intron to ensure quantitation was
assessed only on amplified cDNA. Multiplex PCR was carried out
incorporating  33P-ATP using primers for b-actin as an internal
control. The reaction was stopped and 5 ml of product removed 3
times between cycles 16 and 30 to ensure linear amplification and
the products were run on a denaturing acrylamide gel prior to
autoradiography. The primer sequences are Id3 (5¢-CTCCG-
GAACTTGTCATCTCCAACG and 5¢-GTTCATAAATCAGGGC-
AACAGAACA), b-actin (5¢-CGTGACAAT AAGGAGAAGCTG-
TGC and 5¢-CTCAGGAGGAGCAATGATCTTGAT) and GAPDH
(5¢-ATGGATCCAGTCCATGCCATCACTGCC and 5¢ATGGTAC-
CGAGGTCCACCACCCTGTTG). 
Northern blot analysis 
RNA was denatured and electrophoresed on a formaldehyde-
agarose gel and transferred to a nylon membrane (Amersham
Hybond N+) by capillary blotting overnight according to standard
protocols (Sambrook et al, 1989). The RNA was then fixed to the
membrane by UV irradiation. Probes were prepared from RT-PCR
products by random priming (Amersham Megaprime) and
hybridization was carried out for 2 hours in ExpressHyb solution
(Clontech, Inc.) at 65˚C (for random primed probes) before a 
standard washing procedure. 
Protein extraction and Western blotting 
Harvested cells were lysed by freeze-thawing in 25 mM HEPES,
pH 8, 0.25 M sucrose, 1 mM EGTA, 5 mM MgSO4, 50 mM NaF,
1 mM DTT and protease inhibitors (Complete™ protease
inhibitors cocktail, Boehringer Mannheim), followed by mild
sonication. Cell debris was removed by centrifugation and protein
concentrations determined using the BioRad Protein Assay
reagent. Proteins and prestained SDS-PAGE standards (Biorad)
were electrophoresed on a 15% SDS-PAGE and then elec-
troblotted onto Hybond-C membrane (Amersham). The membrane
was washed in 0.1% Tween 20 (PBT) and blocked with 5% skim
milk powder before incubating with 0.01 mml–1 affinity purified,
rabbit polyclonal anti-Id3 antibody (Santa Cruz) or 1:200 anti b-
actin antibody (Sigma) overnight. The membrane was then354 JM Arnold et al
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incubated with the appropriate HRP-conjugated secondary anti-
body for 2 hours before washing, followed by enzyme chemilumi-
nescence and autoradiography. 
Loss of heterozygosity (LOH) analyses 
LOH was analysed at 1p36 with the D1S2734 marker. PCR ampli-
fication was carried out for 35 cycles in the presence of 33P-dATP
and PCR products were analysed on a denaturing polyacrylamide
gel. LOH was scored conservatively as a substantial reduction in
the intensity of one allele by two independent observers one of
whom was blind with respect to sample identity. 
Single strand conformation polymorphism analysis 
Primers were designed to amplify the coding exons of the human
Id3. The first exon of 351 bp required two overlapping amplimers
(260 bp [5¢-CAGGCAGGCTCTATAAGTGACC and 5¢-
GTAGCAGTGGTTCATGTCGTCC] and 280 bp [5¢-GTCG-
GAACGCAGTCTGGCCATCG and 5¢-CAGCCCTGTCCCGA
CTTCGAGG]) while the second 85 bp exon was amplified in a
single fragment (266 bp [5¢-CTTCCCATCCAGGTAAGCCTCG
and 5¢-CGACTGCCAACTCCAGGACTTGC]). The third exon of
448 bp encoded only the 3¢UTR and was not screened for muta-
tions. 94 of the available 95 primary ovarian tumours were
screened and constitutional DNA was available from blood in all
cases. DNA samples were amplified in the presence of 33 P-dATP
using standard PCR cycling conditions with annealing at 60˚C,
denatured at 95˚C for 5 minutes and then electrophoresed on 0.5 ´
MDE (FMC Biotech) gel overnight at room temperature. Samples
with aberrantly migrating bands were re-amplified and sequenced
directly using ABI Prism Big Dye terminator cycle sequencing
ready reagent kit (PE Applied Biosystems) and analysed on an
ABI 377 sequencer. 
Statistical analyses 
Survival curves, survival probabilities and estimated mean survival
times were calculated according to the Kaplan-Meier method. The
differences between the survival curves for the Id3-positive and
Id3-negative groups were evaluated using the log rank test. Fisher’s
Exact test was used to evaluate the association between Id3 expres-
sion and LOH at 1p36 and the test for trend was used to examine
association between Id3 expression and stage or grade. 
RESULTS 
A cDNA array containing 588 known human cDNA fragments
fixed to a nylon membrane was used to analyse differences in gene
expression between normal OSE cells and ovarian tumour cell
lines. This array contains cDNAs coding for proteins of many
different functional groups including oncogenes and tumour
suppressor genes. Gene expression in the immortalized OSE line,
HOSE 17.1, was first compared to itself in 2 separate hybridiza-
tions to confirm reproducibility and then to that in 3 arbitrarily
chosen ovarian tumour cell lines derived from serous tumours
(OAW42, PEO1 and JAM). 
A visual comparison was made between the intensities of the
signals from the array genes in each cell line using signal intensi-
ties from housekeeping genes as an internal control. This identi-
fied 17 genes (AXL/UFO tyrosine kinase receptor, p16INK4,
integrin linked kinase, Id3, cAMP dependent transcription factor
ATF4, p21WAF1/CIP1, TFIID subunit TAF1131, intercellular adhesion
molecule-1, neural cadherin, CD44 antigen, fibronectin receptor
alpha subunit, fibronectin receptor beta subunit, bone morphog-
enetic protein-1, monocyte chemotactic protein-1, vascular
endothelial growth factor-related protein, heparin-binding growth
factor-1 and follistatin-related protein) that were expressed at
higher levels in HOSE 17.1 compared with the ovarian cancer cell
lines. Another 10 genes (v-ERBA-related protein EAR-1, v-
ERBA-related protein EAR-2, RAF proto oncogene, galactosyl-
transferase-associated protein kinase, protein kinase CLK,
NADPH cytochrome p450 reductase, transcription factor ETR103,
transcription factor ETR101, integrin alpha 1 and integrin alpha
7B) were expressed at higher levels in all 3 ovarian cancer cell
lines, compared with the HOSE 17.1 cell line. 
From the 17 putative tumour suppressor genes, the 6 with the
greatest differences in levels of expression but not previously
linked to ovarian cancer (cAMP-dependent transcription factor
ATF-4, integrin linked kinase, neural cadherin, intercellular adhe-
sion molecule-1, monocyte chemotactic protein-1 and Id3) were
selected for further analysis by semi-quantitative RT-PCR in
HOSE cell lines, short-term cultures of OSEs and ovarian cancer
cell lines (data not shown). There was no evidence for decreased
expression in the ovarian cancer cell lines compared to the OSE
cells for the cAMP-dependent transcription factor ATF-4, integrin
linked kinase or neural cadherin. In contrast, intercellular adhesion
molecule-1, monocyte chemotactic protein-1 and Id3 were
expressed by all the ovarian surface epithelial cell lines but by only
2/6, 1/4 or 2/5 of the ovarian cancer cell lines tested, respectively.
Id3 has been mapped to chromosome 1, at band 1p36.1 (Deed et al,
1994), a common region of loss of heterozygosity (LOH) in a wide
variety of solid human cancers (Ragnarsson et al, 1999). Previous
studies in our laboratory have found 43% LOH at 1p36 in ovarian
adenocarcinomas (Imyanitov et al, 1999). On the basis of this
LOH data, and the loss of expression of Id3 in most of the ovarian
cancer cell lines examined, we selected Id3 for further study of its
expression and mutation profile in ovarian adenocarcinomas. 
Due to the possible influence of culture conditions on the level
of Id3 RNA expression, RT-PCR was first carried out to compare
expression in peeled (uncultured) OSE cells to HOSE 17.1 and
Hose 17.1
Peeled OSE
JAM
OAW42
PEO1
HEY
SKOV3
COLO316
Id3 433 bp
b-actin 375 bp
A
B
Figure 1 RT-PCR analysis of Id3 expression in peeled (uncultured) OSE
cells, immortalized HOSE cells and ovarian cancer cell lines. RT-PCR was
carried out in a multiplex reaction with b-actin as an internal control on
peeled OSE cells, HOSE 17.1 and ovarian cancer cell lines. PCR products
were removed for analysis at 20, 25 and 30 cycles. The Id3 products after
30 cycles and b-actin products after 20 cycles are shown here Reduced Id3 expression in ovarian cancer 355
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ovarian cancer cell lines (Figure 1). This revealed that the level of
Id3 mRNA expression was similar in the peeled OSE cells to
HOSE 17.1. The HOSE 17.1 cells were therefore used as a control
cell population for the remainder of this investigation due to the
limited availability of peeled OSE cells. Id3 mRNA expression
was not detected by RT-PCR in 2 out of 6 ovarian cancer cell lines
(JAM and SKOV3), while the other 4 cell lines (OAW42, PEO1,
HEY and COLO316) had similar levels to the HOSE 17.1 cells. 
Id3 mRNA expression was further analysed in the cell lines by
Northern blot analysis. Expression was observed in both of the
HOSE cell lines, although the level of expression was lower in
HOSE 1.1 than HOSE 17.1 (Figure 2). Similar amounts of Id3
mRNA to those in HOSE 17.1 were observed in 3 of the ovarian
cancer cell lines (OAW 42, COLO316 and CAOV3) but signific-
antly weaker expression was found in the other 6 cell lines exam-
ined. Western blotting detected a protein of 15 kDa corresponding
to Id3, at similar levels in both of the HOSE cell lines (Figure 3).
However, expression was much lower in 5 of the ovarian cancer
cell lines and almost undetectable in the COLO316 and PEO14
cell lines. 
Having established that the expression of Id3 is lower that the
HOSE cell lines at both the mRNA and protein levels in most of
the ovarian cancer cell lines, we next investigated its expression in
primary ovarian tumours. Expression was analysed on a series of
37 primary ovarian adenocarcinomas using semi- quantitative RT-
PCR with b-actin as an internal control (Figure 4). No expression
at all was detected in 26/37 (70%) cases after 30 cycles of ampli-
fication. The remaining cases had variable levels of expression,
but in most cases appeared to express less Id3 message than the
HOSE cells. This finding was supported by Northern blot analysis
which showed expression in the HOSE cells but in only 1/10
primary tumours examined (Figure 5). RT-PCR was not performed
on this single tumour showing expression by Northern analysis but
a combination of RT-PCR and Northern data showed that Id3
expression was not detected in 26/38 (68%) primary tumours. 
To investigate the molecular basis of the down-regulation of Id3
in primary ovarian adenocarcinomas, the Id3 gene was analysed
for mutations in a series of 94 primary ovarian tumours using
single strand conformation polymorphism (SSCP) analysis. This
included 37 of the tumours for which we had Id3 expression data.
There was only one nucleotide change detected in the entire series,
which was a G to A conversion resulting in the change of codon
105 from GCT (alanine) to ACT (threonine) (Table 1). Both the
tumour and the corresponding constitutional DNA were hetero-
zygous for this change. LOH at 1p36 was assessed with the
D1S2734 microsatellite marker in the cases for which Id3
expression had been analysed. LOH was detected in 9/30 (30%)
informative cases. 
Analysis of the survival data for the patients whose tumours
expressed Id3, compared to those whose tumours did not, revealed
a weak relationship between Id3 expression and improved
survival, although this was not significant (P = 0.43, log rank test).
No correlation was found between lack of Id3 expression and
LOH at 1p36 (P = 0.68, Fisher’s Exact test), nor was there any
trend towards loss of expression with higher stage (P = 1.0, Test
for Trend) or grade (P = 0.68, Test for Trend). 
DISCUSSION 
We have used cDNA array analysis to investigate differences
between human ovarian surface epithelial (HOSE) cell lines and 3
serous ovarian cancer cell lines in the expression of a panel of 588
known human genes. A total of 17 genes were identified with
reduced expression and another 10 genes with higher expression in
the ovarian cancer cell lines compared to the HOSE cell line.
Wang et al (1999) and Schummer (1999) also used cDNA microar-
rays to monitor gene expression changes in ovarian tumours
compared to normal ovaries. There were no common genes
between those identified in our study and those in the top 15 over-
expressed or under-expressed known genes reported by Wang et al
(1999) or the 43 known genes found to be over-expressed by
Schummer et al (1999). This may be a reflection of the different
cDNAs included in the respective arrays. 
Many of the genes indicated in this study as being over- or
under-expressed in the ovarian cancer cell lines are well-studied
tumour suppressor genes (eg p16INK4 and p21WAF1/CIP1) or onco-
genes (e.g. c-raf ). Several of the other genes shown to be differen-
tially expressed have been reported as having a role in the control
of cell growth or transformation, such as the AXL/UFO tyrosine
kinase receptor (Janssen et al, 1991), the fibronectin receptor
(reviewed in Ruoslahti 1996), the cAMP-dependent transcription-
factor, ATF-4 (Mielnicki et al, 1996) and the galactosyltransferase-
associated protein kinase (Li et al, 1995). Therefore, on the 
basis of the reported functions of the genes that are apparently
HOSE 17.1
HOSE 1.1
PEO1
OAW42
JAM
HEY
SKOV3
COLO316
PEO14
Id3
15 kDa
b-actin
43 kDa
A
B
Figure 3 Western blot analysis of Id3 expression in HOSE and ovarian
cancer cell lines. Each lane contains 20 mg of total cellular protein.
(A) Reactivity with the anti-Id3 antibody; (B) reactivity with the anti-b-actin
antibody 
HOSE 17.1
HOSE 1.1
PEO1
OAW42
JAM
HEY
AKOV3
COLO316
CAOV3
OVCR3
27/87
0.9 kb
2.0 kb
A
B
Figure 2 Northern blot analysis of Id3 expression in HOSE and ovarian
cancer cell lines. Each lane contains 2 mg of polyA+ RNA. (A) Hybridization
with the Id3 probe, (B) hybridization with the b-actin probe 356 JM Arnold et al
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Figure 4 RT-PCR analysis of Id3 expression in ovarian primary tumours. RT-PCR was carried out in a multiplex reaction with b-actin as an internal control for
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Figure 5 Northern blot analysis of Id3 expression in ovarian primary tumours. Each lane contains 5 mg of total RNA. (A) Hybridization with the Id3 probe; 
(B) hybridization with GAPDH probe. 
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differentially expressed in the ovarian cancer cell lines compared
to the HOSE, most appear to be plausible candidates for a role in
ovarian cancer. 
The Id (inhibitor of differentiation/DNA binding) proteins
belong to a class of transcription factors known as the helix-loop-
helix (HLH) proteins as they contain an amino acid sequence
predicted to form a helix-loop-helix structure which mediates the
dimerization of these proteins (Murre et al, 1989). A sub-group of
HLH proteins, termed the basic HLH proteins (bHLH), contain a
domain of basic amino acids amino-terminal to the HLH domain
which mediates the binding of these protein dimers to a DNA
sequence element called the E-box (CANNTG), leading to G1 cell
cycle arrest and the transcription of differentiation-specific genes
(Murre et al, 1989; Blackwell and Weintraub, 1990). The four
Id proteins lack the basic DNA-binding domain and their
heterodimerization with other bHLH transcription factors inhibits
DNA-binding and inactivates transcription in a dominant negative
manner, thus inhibiting lineage-specific gene expression
(reviewed in Norton et al, 1998; Israel et al, 1999). 
An accumulating body of expression and functional evidence
suggests that the Id proteins may function as oncogenes. In
addition to inhibiting G1 cell cycle arrest and differentiation, Id
genes have been shown to enhance cell cycle progression
(reviewed in Norton et al, 1998; Israel et al, 1999). Over-expres-
sion of Id genes can induce apoptosis in serum-deprived fibro-
blast cells and co-transfection of Id3 with the anti-apoptotic
Bc12 or Bc1XL genes results in immortalization of primary rat
embryo fibroblasts (Norton and Atherton, 1998). Furthermore,
Id gene expression has been reported in human cell lines derived
from a variety of different tumours (Israel et al, 1999) and Id
proteins are required for vascularization of tumours (Lyden et
al, 1999). 
Despite this putative oncogenic role, Northern and Western blot
data presented here indicate that the expression of Id3 is reduced
in most ovarian cancer cell lines relative to uncultured or immor-
talized OSE cells. Furthermore expression of Id3 was not detected
at the mRNA level in 26/38 (68%) of primary tumours. However,
there was no association between lack of expression and LOH on
1p36, nor did we find any mutations in the Id3 gene. These data
suggest that Id3 is not the target of LOH at 1p36. Whether it func-
tions as a type II tumour suppressor gene, down-regulated in
ovarian tumours, is yet to be determined. 
Table 1 Id3 expression, 1p36 LOH status, SSCP results and clinicopathological data for 38 primary ovarian cancers 
Expression LOH 1p36 
Case Histo Stage Grade Nthrn RT PCR D1S2734 SSCP shift 
69/89 SER 3 2 – – NL no 
35/90 SER 3B 2/3 – – L no 
5/91 SER 3 2 XXX Nl no 
7/91 SER 3 2 XXX L no 
16/91 SER 2 3 X NL no 
33/91 ENDO 4 3 – – NL no 
45/91 SER 3C NA – NL no 
46/91 ENDO 3B 2 – NL no 
52/91 SER 2B 2 – NL no 
62/91 SER 3 3 – – no 
68/91 SER 3 3 – NL no 
78/91 SER 3 2/3 XX NL no 
2/92 SER 3 2 – – NL no 
3/92 SER 3 3 X L no 
4/92 SER 3B 3 – L no 
23/92 SER 3 3 – NL not tested 
26/92 CCC 4 2 X NL no 
39/92 SER 3 2 – NL no 
49/92 CCC 3B NA – no 
52/92 SER 3 2 – – L no 
62/92 SER 3C 2/3 – NL no 
66/92 ENDO 3C 3 – NS no 
67/92 ENDO 1C 2/3 XX NL no 
76/92 SER 3 2/3 – NL no 
3/93 SER 3C 3 – NL no 
6/93 SER 3C 2/3 XX NL no 
8/93 SER 3C 2/3 – – Nl no 
10/93 SER 3C 2/3 – NS no 
13/93 SER 3C NA – – L no 
35/93 SER 3C 3 – L G to Aa
61/93 ENDO 4 2 – NL no 
65/93 ENDO 3 2/3 – – L no 
99/93 ENDO 4 3 XX NL no 
108/93 SER 3C 2 XX NL no 
23/94 SER 3 3 – no 
25/94 SER 3C 2 – no 
34/94 SER 3C 3 X L no 
90/94 SER 4 2 X NL no 
apolymorphism = present also in constitutional DNA. NA = not available; – = no expression detected; x, xx and xxx = increasing levels of expression; NL = no
loss; NI = not informative; L = loss; NS = not scored as alleles too close together. ACKNOWLEDGEMENTS 
We thank T Hurst for culturing the OSE cells. This work was
supported by the Queensland Cancer Fund and National Health
and Medical Research Council of Australia. 
REFERENCES 
Blackwell TK and Weintraub H (1990) Differences and similarities in DNA-binding
preferences of MyoD and E2A protein complexes revealed by binding site
selection. Science 250: 1104–1110 
Bruening W, Prowse AH, Schultz DC, Holgado-Madruga M, Wong A and Godwin
AK (1999) Expression of OVCA1, a candidate tumour suppressor, is reduced
in tumours and inhibits growth of ovarian cancer cells. Cancer Res 59:
4973–4983 
Buick RN, Pullano R and Trent JM (1985) Comparative proterties of five human
ovarian adenocarcinoma cell lines. Cancer Res 45: 3668–3676 
Chenevix-Trench G, Leary J, Kerr J, Michel J, Kefford R, Hurst T, Parsons P,
Friedlander M and Khoo SK (1992) Frequent loss of heterozygosity on
chromosome 18 in ovarian adenocarcinoma which does not always include the
DCC locus. Oncogene 7: 1059–1065 
Deed RW, Hirose T, Mitchell ELD, Santibanez-Koref MF and Norton JD (1994)
Structural organisation and chromosomal mapping of the human Id-3 gene.
Gene, 151: 309–314 
Fogh J and Trempe G (1975) New human cell lines. In: Fogh J (ed) Human tumour
cells in vitro, pp 155–159., Plenum: New York 
Foster KA, Harrington P, Kerr J, Russell P, DiCoccio RA, Scott IV, Jacobs I,
Chenevix-Trench G, Ponder BAJ and Gayther SA (1996) Somatic and
germline mutations of the BRCA2 gene in sporadic ovarian cancer. Cancer Res
56: 3622–3625 
Hamilton TC, Young RC, McKoy WM, Grotzinger KR, Green JA, Chu EW, Whang-
Peng J, Rogan AM, Green WR and Ozols RF (1983) Characterization of a
human ovarian carcinoma cell line (NIH:OVCAR-3) with androgen and
estrogen receptors. Cancer Res 43: 5379–5389 
Imyanitov EN, Birrell GW, Filippovich I, Sorokina N, Arnold J, Mould M, Wright
K, Walsh M, Mok SC, Lavin MF, Chenevix-Trench G and Khanna KK (1999)
Frequent loss of heterozygosity at 1p36 in ovarian adenocarcinoma but the
gene encoding p73 is unlikely to be the target, Oncogene 18: 4640–4642 
Israel MA, Hernandez M-C, Florio M, Andres-Barquin PJ, Mantani A, Carter JH
and Julin CM (1999) Id gene expression as a key mediator of tumour cell
biology. Cancer Res 59: 1726s–1730s 
Janssen JW, Schulz AS, Steenvoorden AC, Schmidberger M, Strehl S, Ambros PF
and Bartram CR (1991) A novel putative tyrosine kinase receptor with
oncogenic potential. Oncogene 6: 2113–2120 
Kohler M, Janz I, Wintzer HO, Wagner E and Bauknecht T (1989) The expression of
EGF receptors, EGF-like factors and c-myc in ovarian and cervical carcinomas
and their potential clinical significance. Anticancer Res 9: 1537–1548 
Kruk PA, Maines-Bandiera SL and Auersperg NA (1990) Simplified method to
culture ovarian surface epithelium. Laboratory Investigation 63: 132–136 
Langdon SP, Lawrie SS, Hay FG, Hawkes MM, McDonald A, Hayward IP, School
DJ, Hilgers J, Leonard RCF and Smyth JF (1988) Characterization and
properties of nine human ovarian adenocarcinoma cell lines. Cancer Res 48:
6166–6172 
Leary JA, Kerr J, Chenevix-Trench G, Doris CP, Hurst T, Houghton CRS and
Friedlander ML (1995) Increased expression of the NME1 gene is associated
with metastasis in epithelial ovarian cancer. Int J Cancer 64: 189–195 
Lee SW, Tomasetto C and Sager R (1991) Positive selection of tumour suppressor
genes by subtractive hybridisation. Proc Natl Acad Sci USA 88: 2825–2829 
Li S, MacLachlan TK, De Luca A, Claudio PP, Condorelli G and Giordano A (1995)
The cdc-2-related kinase, PISSLRE, is essential for cell growth and acts in G2
phase of the cell cycle. Cancer Res 55: 3992–3995 
Liang P and Pardee AB (1992) Differential display of eukaryotic messenger RNA by
means of the polymerase chain reaction. Science 257: 967–971 
Lin H, Huber R, Schlessinger D and Morin PJ (1999) Frequent silencing of the
GPC3 gene in ovarian cancer cell lines. Cancer Res 59: 807–810 
Lyden D, Young AZ, Zagzag D, Yan W, Garald W, O’Reilly R, Bader RO, Zhuang
A, Manova K and Benezra R (1999) Id1 and Id3 are required for neurogenesis,
angiogenesis and vascularization of tumour xenografts. Nature 401: 670–677 
Mandai M, Konishi I, Kuroda H, Komatsu T, Yamamoto S, Nanbu K, Matsushita K,
Fukumoto M, Yamabe H and Mori T (1998) Heterogeneous distribution of K-
ras-mutated epithelia in mucinous ovarian tumours with special reference to
histopathology. Hum Pathol 29: 34–40 
Merajver SD, Pham TM, Caduff RF, Chen M, Poy EL, Cooney KA, Weber BL,
Collins FS, Johnston C and Frank TS (1995) Somatic mutations in the BRCA1
gene in sporadic ovarian tumours. Nature Genetics 9: 439–443 
Mielnicki LM, Hughes RG, Chevray PM and Pruitt SC (1996) Mutated ATF-4
suppresses c-Ha-ras oncogene transcript levels and cellular transformation in
NIH3T3 fibroblasts. Biochem Biophys Res Comm 228: 586–595 
Mok SC, Chan WY, Wong KK, Muto MG and Berkowitz RS (1996) SPARC, an
extracellular matrix protein with tumour-suppressing activity in human ovarian
epithelial cells. Oncogene 12: 1895–1901 
Mok SC, Chan WY, Wong KK, Cheung KK, Lau CC, Ng SW, Baldini A, Colitti CV,
Rock CO and Berkowitz RS (1998) DOC-2, a candidate tumour suppressor
gene in human epithelial ovarian cancer. Oncogene 16: 2381–2387 
Murre C, McCaw PS and Baltimore D (1989) A new DNA binding and dimerization
motif in immunoglobulin enhancer binding, daughterless, in MyoD, and myc
proteins. Cell 56: 777–783 
Norton JD and Atherton GT (1998) Coupling of cell growth control and apoptosis
functions of Id proteins. Mol Cell Biol 18: 2371–2381 
Norton JD, Deed RW, Craggs G and Sablitzky F (1998) Id helix-loop-helix proteins
in cell growth and differentiation. Trends Cell Biol 8: 58–65 
Obata K, Morland SJ, Watson RH, Hitchcock A, Chenevix-Trench G, Thomas EJ
and Campbell IG (1998) Frequent PTEN/MMAC mutations in endometrioid
but not serous or mucinous epithelial ovarian tumours. Cancer Res 58:
2095–2097 
O’Bryan JP, Frye RA, Cogswell PC, Neubauer A, Kitch B, Prokop C, Espinosa R,
Le Beau MM, Earp HS and Liu ET (1991) ax1, a transforming gene isolated
from primary human myeloid leukemia cells, encodes a novel receptor tyrosine
kinase. Mol Cell Biol 11: 5016–5031 
Parkin DM, Pisani P and Ferlay J (1999) Estimates of the worldwide incidence of 25
major cancers in 1990. Int J Cancer 80: 827–841 
Peitu G, Alibert O, Guichard V, Lanny B, Bois F, Leroy E, Mariage-Samson R,
Houlgatte R, Soularue P and Auffray C (1996) Novel gene transcripts
preferentially expressed in human muscles revealed by quantitative
hybridization of a high density cDNA array. Genome Res 6: 492–503 
Ragnarrson G, Eiriksdottir G, Johannsdottir JT, Jonasson JG, Egilsson V and
Ingvarsson S (1999) Loss of heterozygosity at chromosome 1p in different
solid human tumours: association with survival. Br J Cancer 79: 1468–1474 
Ruoslahti E (1996) Integrin signalling and matrix assembly. Tumour Biol 17:
117–124 
Sager R (1997) Expression genetics in cancer: shifting the focus from DNA to RNA.
Proc Natl Acad Sci USA 94: 952–955 
Sambrook J, Fritch EF and Maniatis T (1989) Molecular cloning: A laboratory
manual, second edition. Cold Spring Harbor Laboratory Press: New York 
Schena M, Shalon D, Davis RW and Brown PO (1995) Quantitative monitoring of
gene expression patterns with a complementary DNA microarray. Science 270:
467–470 
Schummer M, Ng WV, Bumgarner RE, Nelson PS, Schummer B, Bednarski DW,
Hassel L, Baldwin RL, Karlan BY and Hood L (1999) Comparative
hybridisation of an array of 21 500 ovarian cDNAs for the discovery of genes
overexpressed in ovarian carcinomas. Gene 238: 375–385 
Shelling AN, Cooke IE and Ganesan TS (1995) The genetic analysis of ovarian
cancer. Br J Cancer 72: 521–527 
Shih Y, Kerr J, Liu J, Hurst T, Khoo S, Ward B, Wainwright B and Chenevix-Trench
G (1997) Rare mutations and no hypermethylation at the CDKN2A locus in
epithelial ovarian tumours. Int J Cancer 70: 508–511 
Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, Levin WJ,
Stuart SG, Udove J, Ullrich A and Press MF (1989) Studies of the HER-2/neu
proto-oncogene in human breast and ovarian cancer. Science 244: 707–712 
Tsao S-W, Mok SC, Fey EG, Fletcher JA, Wan TSK, Chew E-C, Muto MG, Knapp
RC and Berkowitz RS (1995) Characterization of human ovarian surface
epithelial cells immortalized by human papilloma viral oncogenes (HPV-E6E7
ORFs). Exp Cell Res 218: 499–507 
Vasmatzis G, Essand M, Brinkmann U, Lee B and Pastan L (1998) Discovery of
three genes specifically expressed in the human prostate by expressed sequence
tag database analysis. Proc Natl Acad Sci USA 95: 300–304 
Velculescu VE, Zhang L, Vogelstein B and Kinzler KW (1995) Serial analysis of
gene expression. Science 270: 484–487 
Wang K, Gan L, Jeffery E, Gayle M, Gown AM, Skelly M, Nelson PS Ng WV,
Schummer M, Hood L and Mulligan J (1999) Monitoring gene expression profile
changes in ovarian carcinomas using cDNA microarray. Gene 229: 101–108 
Ward BG, Wallace K, Shepherd JH and Balkwill FR (1987) Intraperitoneal xenografts
of human epithelial ovarian cancer in nude mice. Cancer Res 47: 2662–2667 
Wilson AP (1984) Characterization of a cell line derived from the ascites of a patient
with papillary serious cystadenocarcinoma of the ovary. J Natl Cancer Inst 72:
513–520 
358 JM Arnold et al
British Journal of Cancer (2001) 84(3), 352–359 © 2001 Cancer Research CampaignReduced Id3 expression in ovarian cancer 359
British Journal of Cancer (2001) 84(3), 352–359 © 2001 Cancer Research Campaign
Wilson AP, Ford CHJ, Newman CE and Howell A (1987) Cis-platinum and ovarian
carcinoma: in vitro chemosensitivity of cultured tumour cells from patients
receiving high dose cis-platinum as first line treatment. Br J Cancer 56: 763–773 
Wolf CR, Hayward IP, Lawrie SS, Buckton K, McIntyre MA, Adams DJ, Lewis AD,
Scott ARR and Smyth JF (1987) Cellular heterogeneity and drug resistance in
two ovarian adenocarcinoma cell lines derived from a single patient. Int J
Cancer 39: 695–702 
Wong AST, Maines-Bandiear SL, Rosen B, Wheelock MJ, Johnson KR, Leung
PCK, Roskelley CD and Auersperg N (1999) Constitutive and conditional
cadherin expression in cultured human ovarian surface epithelium: influence of
family history on ovarian cancer. Int J Cancer 81: 180–188 
Woods LK, Morgan RT, Quinn LA, Moore GE, Semple TU and Stedman KE (1979)
Comparison of four new cell lines from patients with adenocarcinoma of the
ovary. Cancer Res 39: 4449–4459 
Wright K, Wilson P, Morland S, Campbell I, Walsh M, Hurst T, Ward B, Cummings
M and Chenevix-Trench G (1999) Beta-catenin mutation and expression
analysis in ovarian cancer: exon 3 mutations and nuclear translocation in 16%
of endometrioid tumours. Int J Cancer 82: 625–629 
Yasue H, Takeda A and Ishibashi M (1987) Amplification of the c-myc gene and the
elevation of its transcripts in human ovarian tumour lines. Cell Struct Funct 12:
121–126 
Yu Y, Xu F, Peng H, Fang X, Zhao S, Li Y, Cuevas B, Kuo W-L, Gray JW, Siciliano
M, Mills GB and Blast Jr RC (1999) NOEY2 (ARH1), an imprinted putative
tumour supressor gene in ovarian and breast carcinomas. Proc Natl Acad Sci
USA 96: 412–219 
Zhou DJ, Gonzalez-Cadavid N, Ahuja H, Battifora H, Moore GE and Cline MJ
(1988) A unique pattern of proto-oncogene abnormalities in ovarian
adenocarcinomas. Cancer 62: 1573–1579 